| Year |
Citation |
Score |
| 2019 |
Witt NA, Lee B, Ghent K, Zhang WQ, Pehrson AL, Sanchez C, Gould GG. Vortioxetine reduces marble burying but only transiently enhances social interaction preference in adult male BTBR TItpr3/J mice. Acs Chemical Neuroscience. PMID 31468969 DOI: 10.1021/Acschemneuro.9B00386 |
0.374 |
|
| 2018 |
Hillhouse TM, Merritt CR, Smith DA, Cajina M, Sanchez C, Porter JH, Pehrson AL. Vortioxetine Differentially Modulates MK-801-Induced Changes in Visual Signal Detection Task Performance and Locomotor Activity. Frontiers in Pharmacology. 9: 1024. PMID 30271344 DOI: 10.3389/Fphar.2018.01024 |
0.753 |
|
| 2017 |
Dale E, Grunnet M, Pehrson AL, Frederiksen K, Larsen PH, Nielsen J, Stensbøl TB, Ebert B, Yin H, Lu D, Liu H, Jensen TN, Yang CR, Sanchez C. The multimodal antidepressant vortioxetine may facilitate pyramidal cell firing by inhibition of 5-HT3 receptor expressing interneurons: An in vitro study in rat hippocampus slices. Brain Research. PMID 29274875 DOI: 10.1016/J.Brainres.2017.12.025 |
0.398 |
|
| 2017 |
Hlavacova N, Li Y, Pehrson A, Sanchez C, Bermudez I, Csanova A, Jezova D, Franklin M. Effects of vortioxetine on biomarkers associated with glutamatergic activity in an SSRI insensitive model of depression in female rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 29269186 DOI: 10.1016/J.Pnpbp.2017.07.008 |
0.402 |
|
| 2017 |
Pérez PD, Ma Z, Hamilton C, Sánchez C, Mørk A, Pehrson AL, Bundgaard C, Zhang N. Acute effects of vortioxetine and duloxetine on resting-state functional connectivity in the awake rat. Neuropharmacology. PMID 29104073 DOI: 10.1016/J.Neuropharm.2017.10.038 |
0.386 |
|
| 2017 |
Li Y, Pehrson AL, Oosting RS, Gulinello M, Olivier B, Sanchez C. A study of time- and sex-dependent effects of vortioxetine on rat sexual behavior: Possible roles of direct receptor modulation. Neuropharmacology. PMID 28414050 DOI: 10.1016/J.Neuropharm.2017.04.017 |
0.327 |
|
| 2017 |
Nackenoff AG, Simmler LD, Baganz NL, Pehrson AL, Sánchez C, Blakely RD. Serotonin Transporter-Independent Actions of the Antidepressant Vortioxetine as Revealed Using the SERT Met172 Mouse. Acs Chemical Neuroscience. PMID 28272863 DOI: 10.1021/Acschemneuro.7B00038 |
0.383 |
|
| 2017 |
Waller JA, Tamm JA, Abdourahman A, Pehrson AL, Li Y, Cajina M, Sánchez C. Chronic vortioxetine treatment in rodents modulates gene expression of neurodevelopmental and plasticity markers. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 28108062 DOI: 10.1016/J.Euroneuro.2016.11.014 |
0.325 |
|
| 2016 |
Prus AJ, Wise LE, Pehrson AL, Philibin SD, Bang-Andersen B, Arnt J, Porter JH. Discriminative stimulus properties of 1.25 mg/kg clozapine in rats: mediation by serotonin 5-HT2and dopamine D4 receptors. Brain Research. PMID 27502027 DOI: 10.1016/J.Brainres.2016.08.004 |
0.796 |
|
| 2016 |
Pehrson AL, Hillhouse TM, Haddjeri N, Rovera R, Porter JH, Mork A, Smagin G, Song D, Budac D, Cajina M, Sanchez C. Task- and treatment length-dependent effects of vortioxetine on scopolamine-induced cognitive dysfunction and hippocampal extracellular acetylcholine in rats. The Journal of Pharmacology and Experimental Therapeutics. PMID 27402279 DOI: 10.1124/Jpet.116.233924 |
0.757 |
|
| 2016 |
Smagin GN, Song D, Budac DP, Waller JA, Li Y, Pehrson AL, Sánchez C. Histamine may contribute to vortioxetine's procognitive effects; possibly through an orexigenic mechanism. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 26945513 DOI: 10.1016/J.Pnpbp.2016.03.001 |
0.413 |
|
| 2016 |
Nackenoff A, Simmler L, Baganz N, Pehrson A, Sanchez C, Blakely R. A study of chronic vortioxetine in the SERT Met172 mouse suggests antidepressant-like properties that do not require serotonin transporter inhibition European Neuropsychopharmacology. 26: S252. DOI: 10.1016/S0924-977X(16)31124-5 |
0.305 |
|
| 2015 |
Dale E, Pehrson AL, Jeyarajah T, Li Y, Leiser SC, Smagin G, Olsen CK, Sanchez C. Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function. Cns Spectrums. 1-19. PMID 26346726 DOI: 10.1017/S1092852915000425 |
0.363 |
|
| 2015 |
Li Y, Pehrson AL, Waller JA, Dale E, Sanchez C, Gulinello M. A critical evaluation of the activity-regulated cytoskeleton-associated protein (Arc/Arg3.1)'s putative role in regulating dendritic plasticity, cognitive processes, and mood in animal models of depression. Frontiers in Neuroscience. 9: 279. PMID 26321903 DOI: 10.3389/Fnins.2015.00279 |
0.31 |
|
| 2015 |
Pehrson AL, Jeyarajah T, Sanchez C. Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission. Cns Spectrums. 1-22. PMID 26250622 DOI: 10.1017/S1092852915000486 |
0.374 |
|
| 2015 |
Leiser SC, Iglesias-Bregna D, Westrich L, Pehrson AL, Sanchez C. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism. Journal of Psychopharmacology (Oxford, England). 29: 1092-105. PMID 26174134 DOI: 10.1177/0269881115592347 |
0.345 |
|
| 2015 |
Prus AJ, Mooney-Leber SM, Berquist MD, Pehrson AL, Porter NP, Porter JH. The antidepressant drugs fluoxetine and duloxetine produce anxiolytic-like effects in a schedule-induced polydipsia paradigm in rats: enhancement of fluoxetine's effects by the α2 adrenoceptor antagonist yohimbine. Behavioural Pharmacology. 26: 489-94. PMID 26154437 DOI: 10.1097/Fbp.0000000000000159 |
0.794 |
|
| 2015 |
Leiser SC, Li Y, Pehrson AL, Dale E, Smagin G, Sanchez C. Serotonergic Regulation of Prefrontal Cortical Circuitries Involved in Cognitive Processing: A Review of Individual 5-HT Receptor Mechanisms and Concerted Effects of 5-HT Receptors Exemplified by the Multimodal Antidepressant Vortioxetine. Acs Chemical Neuroscience. 6: 970-86. PMID 25746856 DOI: 10.1021/Cn500340J |
0.361 |
|
| 2015 |
Bétry C, Overstreet D, Haddjeri N, Pehrson AL, Bundgaard C, Sanchez C, Mørk A. A 5-HT3 receptor antagonist potentiates the behavioral, neurochemical and electrophysiological actions of an SSRI antidepressant. Pharmacology, Biochemistry, and Behavior. 131: 136-42. PMID 25697477 DOI: 10.1016/J.Pbb.2015.02.011 |
0.413 |
|
| 2015 |
Bétry C, Etiévant A, Pehrson A, Sánchez C, Haddjeri N. Effect of the multimodal acting antidepressant vortioxetine on rat hippocampal plasticity and recognition memory Progress in Neuro-Psychopharmacology and Biological Psychiatry. 58: 38-46. PMID 25524057 DOI: 10.1016/J.Pnpbp.2014.12.002 |
0.462 |
|
| 2015 |
Pehrson AL, Leiser SC, Gulinello M, Dale E, Li Y, Waller JA, Sanchez C. Treatment of cognitive dysfunction in major depressive disorder--a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. European Journal of Pharmacology. 753: 19-31. PMID 25107284 DOI: 10.1016/J.Ejphar.2014.07.044 |
0.326 |
|
| 2015 |
Pehrson A, Haddjeri N, Hillhouse T, Rovera R, Porter J, Mork A, Song D, Budac D, Smagin G, Sanchez C. P.2.a.006 Task- and treatment-dependent effects of vortioxetine on scopolamine-induced cognitive dysfunction and cortical extracellular acetylcholine European Neuropsychopharmacology. 25: S378. DOI: 10.1016/S0924-977X(15)30490-9 |
0.748 |
|
| 2014 |
Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mørk A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. The Journal of Pharmacology and Experimental Therapeutics. 350: 589-604. PMID 24947465 DOI: 10.1124/Jpet.114.213793 |
0.419 |
|
| 2014 |
Wallace A, Pehrson AL, Sánchez C, Morilak DA. Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 17: 1695-706. PMID 24852131 DOI: 10.1017/S1461145714000571 |
0.393 |
|
| 2014 |
Leiser SC, Pehrson AL, Robichaud PJ, Sanchez C. Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats. British Journal of Pharmacology. 171: 4255-72. PMID 24846338 DOI: 10.1111/Bph.12782 |
0.384 |
|
| 2014 |
Jensen JB, du Jardin KG, Song D, Budac D, Smagin G, Sanchez C, Pehrson AL. Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 148-59. PMID 24284262 DOI: 10.1016/J.Euroneuro.2013.10.011 |
0.398 |
|
| 2014 |
du Jardin KG, Jensen JB, Sanchez C, Pehrson AL. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 160-71. PMID 23916504 DOI: 10.1016/J.Euroneuro.2013.07.001 |
0.438 |
|
| 2014 |
Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. Cns Spectrums. 19: 121-33. PMID 23903233 DOI: 10.1017/S1092852913000540 |
0.36 |
|
| 2014 |
Oosting R, Chan J, Pehrson A, Li Y, Sanchez C, Olivier B. P.2.e.002 Vortioxetine's multimodal mechanism of action implies an absence of sexual side effects in a male rat model for sexual function European Neuropsychopharmacology. 24: S448. DOI: 10.1016/S0924-977X(14)70716-3 |
0.47 |
|
| 2013 |
Guilloux JP, Mendez-David I, Pehrson A, Guiard BP, Repérant C, Orvoën S, Gardier AM, Hen R, Ebert B, Miller S, Sanchez C, David DJ. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology. 73: 147-59. PMID 23721744 DOI: 10.1016/J.Neuropharm.2013.05.014 |
0.394 |
|
| 2013 |
Bétry C, Pehrson AL, Etiévant A, Ebert B, Sánchez C, Haddjeri N. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 16: 1115-27. PMID 23089374 DOI: 10.1017/S1461145712001058 |
0.4 |
|
| 2013 |
Pehrson AL, Bondi CO, Totah NK, Moghaddam B. The influence of NMDA and GABA(A) receptors and glutamic acid decarboxylase (GAD) activity on attention. Psychopharmacology. 225: 31-9. PMID 22797703 DOI: 10.1007/S00213-012-2792-Z |
0.781 |
|
| 2013 |
Pehrson AL, Cremers T, Bétry C, van der Hart MG, Jørgensen L, Madsen M, Haddjeri N, Ebert B, Sanchez C. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters--a rat microdialysis and electrophysiology study. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 133-45. PMID 22612991 DOI: 10.1016/J.Euroneuro.2012.04.006 |
0.394 |
|
| 2013 |
Mørk A, Pehrson A, Betry C, David D, Li Y, Gulinello M, Leiser S, Haddjeri N, Sánchez C. P.2.e.002 Vortioxetine (Lu AA21004), a multimodal antidepressant: differentiation from current antidepressants in animal models of depression European Neuropsychopharmacology. 23: S392-S393. DOI: 10.1016/S0924-977X(13)70620-5 |
0.404 |
|
| 2012 |
Mørk A, Pehrson A, Brennum LT, Møller Nielsen S, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sánchez C, Fischer CW, Liebenberg N, Wegener G, Bundgaard C, Hogg S, et al. Pharmacological effects of Lu AA21004: A novel multimodal compound for the treatment of major depressive disorder Journal of Pharmacology and Experimental Therapeutics. 340: 666-675. PMID 22171087 DOI: 10.1124/Jpet.111.189068 |
0.444 |
|
| 2012 |
Pehrson A, Nielsen KGdJ, Jensen J, Sanchez C. P.2.d.003 The novel multimodal antidepressant Lu AA21004 improves memory performance in 5-HT depleted rats via 5-HT3 and 5-HT1A receptor mechanisms European Neuropsychopharmacology. 22: S269. DOI: 10.1016/S0924-977X(12)70405-4 |
0.378 |
|
| 2012 |
Sanchez C, Robichaud P, Pehrson A, Leiser S. P.2.b.005 The effects of the multimodal antidepressant Lu AA21004 on attention and vigilance measured as EEG activity in the rat European Neuropsychopharmacology. 22: S243-S244. DOI: 10.1016/S0924-977X(12)70363-2 |
0.314 |
|
| 2011 |
Pehrson A, Cremers T, Westerink B, Jorgensen L, Madsen M, Ebert B, Sanchez C. P.2.d.003 Acute and subchronic Lu AA21004 induces monoamine release through a mechanism involving multiple serotonergic receptors European Neuropsychopharmacology. 21: S403. DOI: 10.1016/S0924-977X(11)70649-6 |
0.309 |
|
| 2010 |
Pehrson AL, Moghaddam B. Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion. Psychopharmacology. 211: 443-55. PMID 20585759 DOI: 10.1007/S00213-010-1914-8 |
0.57 |
|
| 2010 |
Moghaddam B, Pehrson AL. Disinhibition of prefrontal cortex neurons in schizophrenia Advances in Schizophrenia Research 2009. 99-111. DOI: 10.1007/978-1-4419-0913-8_5 |
0.456 |
|
| 2009 |
Prus AJ, Pehrson AL, Philibin SD, Wood JT, Vunck SA, Porter JH. The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic drug clozapine in rats. Psychopharmacology. 203: 295-301. PMID 18685832 DOI: 10.1007/S00213-008-1262-0 |
0.778 |
|
| 2008 |
Prus AJ, Vann RE, Rosecrans JA, James JR, Pehrson AL, O'Connell MM, Philibin SD, Robinson SE. Acute nicotine reduces and repeated nicotine increases spontaneous activity in male and female Lewis rats. Pharmacology, Biochemistry, and Behavior. 91: 150-4. PMID 18644403 DOI: 10.1016/J.Pbb.2008.06.024 |
0.754 |
|
| 2008 |
Pehrson AL, Philibin SD, Gross D, Robinson SE, Vann RE, Rosecrans JA, James JR. The effects of acute and repeated nicotine doses on spontaneous activity in male and female Sprague Dawley rats: analysis of brain area epibatidine binding and cotinine levels. Pharmacology, Biochemistry, and Behavior. 89: 424-31. PMID 18313740 DOI: 10.1016/J.Pbb.2008.01.018 |
0.743 |
|
| 2006 |
Prus AJ, Philibin SD, Pehrson AL, Porter JH. Discriminative stimulus properties of the atypical antipsychotic drug clozapine in rats trained to discriminate 1.25 mg/kg clozapine vs. 5.0 mg/kg clozapine vs. vehicle. Behavioural Pharmacology. 17: 185-94. PMID 16495726 DOI: 10.1097/01.Fbp.0000197457.70774.91 |
0.822 |
|
| 2005 |
Prus AJ, Philibin SD, Pehrson AL, Porter JH. Generalization to atypical antipsychotic drugs depends on training dose in rats trained to discriminate 1.25 mg/kg clozapine versus 5.0 mg/kg clozapine versus vehicle in a three-choice drug discrimination task. Behavioural Pharmacology. 16: 511-20. PMID 16170228 DOI: 10.1097/01.fbp.0000172735.73876.06 |
0.803 |
|
| 2005 |
Philibin SD, Prus AJ, Pehrson AL, Porter JH. Serotonin receptor mechanisms mediate the discriminative stimulus properties of the atypical antipsychotic clozapine in C57BL/6 mice. Psychopharmacology. 180: 49-56. PMID 15696329 DOI: 10.1007/S00213-005-2147-0 |
0.808 |
|
| 2005 |
Prus A, Philibin S, Pehrson A, Wood E, Porter J. A82 THE DISCRIMINATIVE STIMULUS PROPERTIES OF THE ATYPICAL ANTIPSYCHOTIC DRUG CLOZAPINE IN RATS TRAINED TO DISCRIMINATE 1.25???mg/kg CLOZAPINE VERSUS 5.0???mg/kg CLOZAPINE VERSUS VEHICLE IN A THREE-CHOICE DRUG DISCRIMINATION TASK Behavioural Pharmacology. 16: S49. DOI: 10.1097/00008877-200509001-00155 |
0.805 |
|
| 2005 |
Porter J, Cooper R, Prus A, Stephens C, Pehrson A, Wood E, Porter N, Glowa J. A64 THE ??2 ANTAGONIST YOHIMBINE ACCELERATES THE EFFECTS OF THE SSRI FLUOXETINE ON SCHEDULE-INDUCED POLYDIPSIA Behavioural Pharmacology. 16: S43. DOI: 10.1097/00008877-200509001-00136 |
0.761 |
|
| 2005 |
Prus AJ, Philibin SD, Pehrson AL, Stephens CL, Cooper RN, Wise LE, Porter JH. Generalization testing with atypical and typical antipsychotic drugs in rats trained to discriminate 5.0 mg/kg clozapine from vehicle in a two-choice drug discrimination task Drug Development Research. 64: 55-65. DOI: 10.1002/Ddr.10419 |
0.79 |
|
| Show low-probability matches. |